TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signage of a written informed consent~2. Age above 18 years~3. HCC unsuitable for resection~4. Child-Pugh A or B cirrhosis~5. Eastern Cooperative Oncology Group performance score 0 or 1~6. No previous treatment with liver resection, ablation, chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy),~7. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.~8. No extra-hepatic involvement on non-enhanced CT thorax and triphasic contrast enhanced CT abdomen.~9. No invasion of portal vein or hepatic vein~10. Massive expansive tumor morphology with measurable lesion on CT (characterized by well-defined spherical or globular configuration, with or without tumor capsule or satellite lesions)~11. Total tumor mass \< 50% liver volume~12. Size of any individual tumor \>10cm in largest dimension~Exclusion Criteria:~1. History of acute tumor rupture presenting with hemo-peritoneum~2. Biliary obstruction not amenable to percutaneous or endoscopic drainage~3. Child-Pugh C cirrhosis~4. History of hepatic encephalopathy~5. Intractable ascites not controllable by medical therapy~6. History of variceal bleeding within last 3 months~7. Serum total bilirubin level \> 50 umol/L~8. Serum albumin level \< 25g/L~9. INR \> 1.7~10. Serum creatinine level \> 150 mmol/L.~11. Infiltrative tumor morphology (characterized by ill- defined tumor margin and amorphous configuration) or diffuse tumor morphology (characterized by large number of small nodules)~12. Arterio-portal venous shunt affecting \>1 hepatic segment on CT~13. Arterial-hepatic venous shunt with hepatic vein opacified in arterial phase on CT

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE for HCC of size >10cm (Type: OTHER): Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimize RV Selective Site Pacing Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects that are expected to be paced in the right ventricle (RV) greater than 90 percent of the time~* Subjects with an ejection fraction of greater than 40 percent within 3 months prior to enrollment~* Subjects greater than 18 yrs of age~* Subjects that are indicated for a dual chamber pacemaker~* Subjects that will be implanted with a market released dual chamber Medtronic pacemaker and 3830 SelectSecure Lead in the ventricle~Exclusion Criteria:~* Subjects indicated for cardiac resynchronization therapy (CRT) device (based on American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines)~* Subjects indicated for an implantable cardiac defibrillator (ICD)~* Subjects with permanent atrial fibrillation (AF)~* Subjects with expected managed ventricular pacing turned on~* Subjects with a previously implanted pacemaker, ICD, or CRT device~* Subjects with an myocardial infarction (MI) within 3 months prior to enrollment~* Subjects that received bypass surgery within 3 months prior to enrollment~* Subjects that had valve replacement within 3 months prior to enrollment~* Subjects where a RV lead cannot be placed, (i.e., complex congenital heart disease~* Subjects with a mechanical right heart valve~* Women who are pregnant or nursing~* Significant co-morbidity preventing study completion~* Terminal conditions with a life expectancy of less than two years~* Participation in another study that would confound the results of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RV Mid-Septal Pacing (Type: ACTIVE_COMPARATOR): Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
- RV Apical Pacing (Type: ACTIVE_COMPARATOR): Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Protect II, A Prospective, Multicenter Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Subject is indicated for a NON emergent percutaneous treatment of at least on de novo or restenotic lesion in a native coronary vessel or bypass graft.~* Patient presents with:~  * A compromised Ejection Fraction~ * Intervention on the last patent coronary conduit~ * Intervention on an unprotected left main artery or~ * Patient presenting with triple vessel disease.~Exclusion Criteria:~* ST elevation M.I.~* Pre procedure cardiac arrest within 24 hours.~* Subject in cardiogenic shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- IMPELLA LP 2.5 (Type: EXPERIMENTAL): None
- IABP Intra-aortic balloon pump (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Recognizing Pain Intensity in Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for patients with alzheimer's disease :~* Diagnosis of the disease by a hospital doctor after an etiological assessment including at least a cerebral MRI, a neuropsychological assessment and, if possible, dementia markers in the cerebrospinal fluid.~* Mini Mental State Score \> 23~Inclusion Criteria for control subject :~- Matching by age (± 5 years), gender, and grade level~Exclusion Criteria for 2 groups :~* presence of pain,~* Presence of mood and/or psychiatric disorders (HAD A ou A scores \>7).~* Presence of cardiovascular risk factors and beta-blocker and/or calcium channel blocker therapy.~* Patients under guardianship or curatorship

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- patients with alzheimer's disease (Type: OTHER): None
- control subject (Type: OTHER): Matching by age (± 5 years), gender, and grade level

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have histologically or cytologically confirmed ovarian cancers for which carboplatin is an acceptable treatment option. In addition, participants must be candidates for systemic chemotherapy as determined by their treating physician.~* Participants must have received a carboplatin-containing regimen at initial diagnosis. Retreatment is permitted in second or greater line with carboplatin-based chemotherapy.~* Age ≥ 18 years of age~* Eastern Cooperative Oncology Group performance status \<2 (see Appendix A).~* Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to initiating chemotherapy on trial and must agree to practice an effective method of birth control, such as an intrauterine device, tubal ligation, or oral contraceptives, during the study and for six months after their last treatment. Women should not breast-feed while on this study~* Ability to understand and the willingness to sign a written informed consent document~* Patients must be willing to comply with study design and requirements for participating on the study.~* Laboratory Criteria for eligibility The following are laboratory criteria for baseline absolute neutrophil count, platelet count, and creatinine for inclusion on this study.~Exclusion Criteria:~* Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin.~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin (Type: EXPERIMENTAL): Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:~* First hour - Administer 1 percent of total dose (5ml with tubing primed)~* Second hour - Administer 9 percent (45 mL)~* Third hour - Administer 90 percent (450 mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously received ofatumumab or placebo in Trial Hx-CD20-403.~* Patients on methotrexate therapy (7.5 - 25 mg/week, p.o., i.m., and/or s.c.).~* Oral corticosteroids therapy (≤ 10 mg/day prednisolone or equivalent).~* Active disease at the time of screening as defined by:~  * 3 swollen joints (of 28 joints assessed) and ≥ 3 tender joints (of 28 joints assessed), DAS28≥3.2 (based on ESR)~Exclusion Criteria:~* Use of DMARDs other than methotrexate or exposure to other cell depleting therapy, including investigational compounds \< 6 months prior to Visit 2 A.~* Patients who have received treatment with any non-marketed drug substance within 4 weeks prior to Visit 1 (screening).~* Breast feeding women or women with a positive pregnancy test at Visit 1 (screening).~* Received anti-cancer therapy, corticosteroids (intra-articular, i.m., or i.v.), or live/attenuated vaccinations, or exposure to cyclophosphamide, nitrogen mustard, chlorambucil or other alkylating agents \< 5 years prior to screening.~* Past or current malignancy, except for Cervical carcinoma Stage 1B or less, Non-invasive basal cell and squamous cell skin carcinoma, Malignant melanoma with a complete response of a duration of \> 10 years, or other cancer diagnoses with a complete response of a duration of \> 5 years.~* Chronic or ongoing active infectious disease requiring systemic treatment.~* Clinically significant cardiac disease, or history of significant cerebrovascular disease.~Significant concurrent, uncontrolled medical conditions, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease~* Known or suspected HIV positive, positive serology for hepatitis B (HB), positive test for Hepatitis C, or positive plasma or white cell JC virus (JCV) PCR (either compartment).~* A circulating IgG level \<lower limit of normal.~* Known hypersensitivity to components of the investigational medicinal product.~* Patients known or suspected of not being able to comply with a study protocol.~* Women of child bearing potential not will to use adequate contraception during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): 1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Needle-insertion Depth on Successful Epidurogram and Clinical Outcome in Caudal Epidural Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (20-80 years of age) who were scheduled to receive caudal epidural injection for lumbosacral radicular pain at our pain management clinic~Exclusion Criteria:~* pregnancy~* coagulopathy~* systemic infection~* any active infection at the injection site~* history of allergy to contrast media, local anesthetics, corticosteroid~* patients unable to communicate or patients with cognitive dysfunction

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: NO_INTERVENTION): Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
- Group B (Type: EXPERIMENTAL): New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Oxide Monohydrate for Nocturnal Leg Cramps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Signed informed consent before any procedure or assessment is done. Age over 21 years old. Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the treatment phase).~Insured by Clalit Health Services (CHS). Hebrew speaking~Exclusion Criteria:~Pregnancy Currently taking Quinidine or Magnesium additive Renal failure - serum creatinine more than 2 mg/DL or estimated glomerular filtration rate (eGFR) less than 60 ml/min (the worst, ascertained by the participant electronic records in the last 6 months). If the result is near these limits (i.e. serum creatinin 1.5-2) a second analysis will be done near the study enrollment.~Major neurological disease- ALS, MS, Paraplegia or Quadriplegia.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MAGNOX 520® (Type: EXPERIMENTAL): MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
- Similarly looking placebo. (Type: PLACEBO_COMPARATOR): Similarly looking placebo. Oral administration once daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Does VoltagE Guided Additional Ablation Improve Procedural Outcome of Atrial Fibrillation Ablation?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing first-time catheter ablation for AF.~* Willing and able to provide informed consent~* Age greater than or equal to 18 years.~Exclusion Criteria:~* Patients who have previously undergone AF ablation~* Patients with more than mild mitral valve stenosis or mechanical mitral valve replacement~* Patients with chronic renal impairment with creatinine clearance rate of \<30 mL/min~* Patients who are pregnant

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Additional posterior wall isolation (Type: EXPERIMENTAL): Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
- Voltage-guided substrate homogenization (Type: EXPERIMENTAL): Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
- PVI only group (Type: ACTIVE_COMPARATOR): Operator will perform PVI only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male~* age \>18~* biopsy-proven non-small cell lung cancer~* surgical intervention planned~Exclusion Criteria:~* current use of 5-alpha reductase inhibitor~* previous diagnosis of prostate cancer~* previous hypersensitivity to 5-alpha reductase inhibitor

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- finasteride (Type: EXPERIMENTAL): finasteride 5mg po od from study entry to date of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Timing For Embryo Transfer For Low Responder Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing IVF~* Number of mature oocytes equal to or lesser than the maximum number of embryos intended for transfer~Exclusion Criteria:~* Patient nor consenting

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Day 0 Embryo Transfer (Type: EXPERIMENTAL): Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
- Day 2,3 Embryo Transfer (Type: ACTIVE_COMPARATOR): Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Opioid vs. Opioid-free Anesthesia for Hip Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* ASA I-II~* Undergoing elective hip arthroscopy~Exclusion Criteria:~* Known allergies to study drugs~* Opioid use 1 month prior to surgery~* BMI \>30~* Unable to comprehend visual analog scale

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lidocaine/ ketamine infusion (Type: EXPERIMENTAL): lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
- fentanyl (Type: ACTIVE_COMPARATOR): iv fentanyl, 3ug/kg bolus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients age \>18 year with previous diagnosis of Diabetes Mellitus and previous admission for DKA in any facility within the prior 2 years who meet the criteria for DKA at the time of admission and are willing to participate in the study protocol will be enrolled in the study.~DKA is defined as:~1. Serum bicarbonate below 18 mg/dl~2. Anion Gap over greater than or equal to 16~3. Serum ketones or beta hydroxybutyrate elevation \> 3 mmol/L~4. Serum glucose greater than or equal to 250 mg/dl~Exclusion Criteria:~Patients with no previous DKA, patients who are not willing to consent to participate in the study protocol for 1 year, pregnant women, dementia, and end stage renal disease on dialysis.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degludec (Type: EXPERIMENTAL): Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.
- Standard long-acting (Type: ACTIVE_COMPARATOR): Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR \<30 ml/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues